Giulia Taraboletti

List of Publications by Year
in descending order

82 papers	5,737 citations	61984 43 h-index	76900 74 g-index
86 all docs	86 docs citations	86 times ranked	7150 citing authors

#	Article	IF	Citations
1	Molecular Basis of the Antiangiogenic Action of Rosmarinic Acid, a Natural Compound Targeting Fibroblast Growth Factorâ€2/FGFR Interactions. ChemBioChem, 2021, 22, 160-169.	2.6	11
2	Alternative Vascularization Mechanisms in Tumor Resistance to Therapy. Cancers, 2021, 13, 1912.	3.7	28
3	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biology, 2021, 103-104, 22-36.	3.6	2
4	Thrombospondins in bone remodeling and metastatic bone disease. American Journal of Physiology - Cell Physiology, 2020, 319, C980-C990.	4.6	5
5	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. Cells, 2020, 9, 952.	4.1	23
6	ADAMDEC1 Maintains a Growth Factor Signaling Loop in Cancer Stem Cells. Cancer Discovery, 2019, 9, 1574-1589.	9.4	59
7	The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). Angiogenesis, 2019, 22, 133-144.	7.2	37
8	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. Carcinogenesis, 2019, 40, 303-312.	2.8	28
9	Pentraxin 3 regulates synaptic function by inducing AMPA receptor clustering via ECM remodeling andÂÎ²1â€integrin. EMBO Journal, 2019, 38, .	7.8	42
10	Soluble stromaâ€related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	6.9	56
11	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. Diabetes, 2018, 67, 2069-2083.	0.6	8
12	Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Scientific Reports, 2016, 6, 23432.	3.3	20
13	Snail levels control the migration mechanism of mesenchymal tumor cells. Oncology Letters, 2016, 12, 767-771.	1.8	9
14	Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFÎ² and in cooperation with PDGF. Matrix Biology, 2016, 55, 106-116.	3.6	52
15	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. International Journal of Cancer, 2015, 136, 721-729.	5.1	50
16	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. Connective Tissue Research, 2015, 56, 355-363.	2.3	10
17	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clinical and Experimental Metastasis, 2015, 32, 647-658.	3.3	17
18	Thrombospondinâ€1 is part of a Slugâ€independent motility and metastatic program in cutaneous melanoma, in association with <scp>VEGFR</scp>â€1 and <scp>FGF</scp>â€2. Pigment Cell and Melanoma Research, 2015, 28, 73-81.	3.3	45

#	Article	IF	Citations
19	Current understanding of the thrombospondin-1 interactome. Matrix Biology, 2014, 37, 83-91.	3.6	228
20	Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. American Journal of Pathology, 2014, 184, 1050-1061.	3.8	56
21	The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts. Molecular Cancer Therapeutics, 2013, 12, 131-140.	4.1	39
22	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemotherapy and Pharmacology, 2013, 72, 879-887.	2.3	37
23	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. Neoplasia, 2012, 14, 846-IN16.	5.3	28
24	Direct and Allosteric Inhibition of the FGF2/HSPGs/FGFR1 Ternary Complex Formation by an Antiangiogenic, Thrombospondin-1-Mimic Small Molecule. PLoS ONE, 2012, 7, e36990.	2.5	40
25	Targeting angiogenesis with compounds from the extracellular matrix. International Journal of Biochemistry and Cell Biology, 2011, 43, 1674-1685.	2.8	36
26	Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. Pharmaceuticals, 2010, 3, 1241-1278.	3.8	30
27	Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. Journal of Biological Chemistry, 2010, 285, 8733-8742.	3.4	70
28	Combination Therapy with Chemotherapy and VDAs. , 2010, , 77-93.		2
29	Reduced Expression of the ROCK Inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells. PLoS ONE, 2010, 5, e14154.	2.5	54
30	Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget, 2010, 1, 662-673.	1.8	57
31	Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget, 2010, 1, 662-73.	1.8	33
32	Vascular Disrupting Activity of Tubulin-Binding 1,5-Diaryl-1H-imidazoles. Journal of Medicinal Chemistry, 2009, 52, 7906-7910.	6.4	65
33	Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. International Journal of Biochemistry and Cell Biology, 2008, 40, 700-709.	2.8	67
34	Cathepsin B Mediates the pH-Dependent Proinvasive Activity of Tumor-Shed Microvesicles. Neoplasia, 2008, 10, 481-488.	5.3	137
35	Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. Molecular Cancer Research, 2008, 6, 525-534.	3.4	65
36	Microtubule Targeting Agents and the Tumor Vasculature. , 2008, , 519-530.		4

#	Article	IF	Citations
37	Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. British Journal of Cancer, 2007, 97, 888-894.	6.4	49
38	Tumorâ€™host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer and Metastasis Reviews, 2007, 26, 481-488.	5.9	12
39	Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH. Neoplasia, 2006, 8, 96-103.	5.3	168
40	Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. European Journal of Cancer, 2006, 42, 2821-2832.	2.8	90
41	Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. Journal of Bone and Mineral Research, 2005, 21, 207-218.	2.8	64
42	Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. Clinical Cancer Research, 2005, 11, 2720-2726.	7.0	23
43	Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells. Journal of Pathology, 2005, 205, 50-56.	4.5	15
44	Antiangiogenic activity of aplidine, a new agent of marine origin. British Journal of Cancer, 2004, 90, 2418-2424.	6.4	82
45	Modelling approaches for angiogenesis. European Journal of Cancer, 2004, 40, 881-889.	2.8	85
46	ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sciences, 2004, 74, 2975-2985.	4.3	48
47	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	7.2	142
48	Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. European Journal of Cancer, 2003, 39, 1948-1956.	2.8	87
49	IDN 5390: a new concept in taxane development. Anti-Cancer Drugs, 2003, 14, 255-258.	1.4	9
50	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood, 2003, 102, 4399-4406.	1.4	93
51	Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research, 2003, 63, 1534-7.	0.9	94
52	Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Research, 2003, 63, 5224-9.	0.9	241
53	Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial Cells. American Journal of Pathology, 2002, 160, 673-680.	3.8	502
54	Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clinical Cancer Research, 2002, 8, 1182-8.	7.0	50

#	Article	IF	Citations
55	Antiangiogenic and antivascular therapy for cancer. Current Opinion in Pharmacology, 2001, 1, 378-384.	3.5	62
56	Preclinical development of metalloproteasis inhibitors in cancer therapy. Critical Reviews in Oncology/Hematology, 2001, 37, 53-60.	4.4	41
57	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	5.9	51
58	Inhibition of matrix metalloproteinases by overâ€expression of tissue inhibitor of metalloproteinaseâ€2 inhibits the growth of experimental hemangiomas. International Journal of Cancer, 2001, 91, 241-247.	5.1	29
59	Thrombospondinâ€1/HIVâ€1 Tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB Journal, 2000, 14, 1917-1930.	0.5	27
60	The heparin binding 25 kDa fragment of thrombospondinâ€1 promotes angiogenesis and modulates gelatinase and TIMPâ€2 production in endothelial cells. FASEB Journal, 2000, 14, 1674-1676.	0.5	146
61	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. Experimental Cell Research, 2000, 258, 384-394.	2.6	43
62	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	3.8	322
63	CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1500, 227-240.	3.8	48
64	Mesothelial cells induce the motility of human ovarian carcinoma cells. , 1999, 80, 303-307.		44
65	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
66	Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndromeâ€"Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. Blood, 1999, 94, 1747-1754.	1.4	5
67	Increased Tumorigenicity and Invasiveness of C6 Rat Glioma Cells Transfected with the Human {FC12}a-2,8 Sialyltransferase cDNA. Invasion & Metastasis, 1998, 18, 142-154.	0.5	22
68	Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. , 1997, 70, 72-77.		21
69	Expression of the 67 kD Laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. European Journal of Cancer, 1996, 32, 1598-1602.	2.8	39
70	Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases. Journal of the National Cancer Institute, 1995, 87, 293-298.	6.3	220
71	Proliferative and migratory responses of murine microvascular endothelial cells to granulocyte-colony-stimulating factor. Journal of Cellular Physiology, 1993, 155, 89-95.	4.1	66
72	Enhancement of Metastatic Potential of Murine and Human Melanoma Cells by Laminin Receptor Peptide G: Attachment of Cancer Cells to Subendothelial Matrix as a Pathway for Hematogenous Metastasis. Journal of the National Cancer Institute, 1993, 85, 235-240.	6.3	44

#	Article	IF	Citations
73	Matrigel promotes retinoblastoma cell growthin vitro andin vivo. International Journal of Cancer, 1992, 52, 234-240.	5.1	46
74	Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. Exs, 1992, 61, 210-213.	1.4	15
75	Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.. Journal of Cell Biology, 1990, 111, 765-772.	5.2	392
76	Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochemical and Biophysical Research Communications, 1990, 169, 165-170.	2.1	166
77	Modulation of Laminin Receptor Expression by Estrogen and Progestins in Human Breast Cancer Cell Lines. Journal of the National Cancer Institute, 1989, 81, 781-789.	6.3	81
78	Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. International Journal of Cancer, 1989, 44, 707-713.	5.1	99
79	Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. European Journal of Cancer & Clinical Oncology, 1987, 23, 1529-1535.	0.7	39
80	Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration. Nature, 1987, 329, 261-263.	27.8	145
81	The Macrophage Content of Tumors Is Unrelated to Levels of NK Cell-Mediated Resistance. Journal of Leukocyte Biology, 1986, 39, 113-119.	3.3	3
82	Tumor-derived chemotactic factor(S) from human ovarian carcinoma: Evidence for a role in the regulation of macrophage content of neoplastic tissues. International Journal of Cancer, 1985, 36, 167-173.	5.1	59